{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T05:00:17Z","timestamp":1780981217610,"version":"3.54.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>ALK-positive anaplastic large cell lymphoma (ALCL) is a rare T-cell lymphoma, typically associated with a favorable prognosis. However, outcomes in refractory or relapsed ALK-positive ALCL with central nervous system (CNS) involvement are poor, and no standard therapy has been established. Emerging data suggest that ALK inhibitors may be safe and effective for CNS ALK-positive ALCL. Here, we present two cases of ALK-positive ALCL with CNS involvement. The first patient, an 18-year-old male was diagnosed with ALK-positive ALCL and achieved complete remission after six cycles of chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) but subsequently relapsed in the CNS. He received intrathecal chemotherapy and alectinib, followed by consolidation with allogeneic HSCT, and has remained in remission for over 81 months on alectinib maintenance. The second patient, a 31-year-old woman, presented with symptoms of meningitis and was diagnosed with ALK-positive ALCL with primary isolated CNS involvement. She received alectinib combined with CNS-directed chemotherapy and has remained in complete remission for 20 months on alectinib maintenance. These cases suggest that alectinib, combined with CNS-directed chemotherapy, is effective in both ALK-positive ALCL with CNS relapse and primary isolated CNS disease.<\/jats:p>","DOI":"10.3389\/fonc.2026.1679620","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:28:02Z","timestamp":1780979282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Alectinib and CNS-directed therapy for primary or relapsed ALK-positive anaplastic large cell lymphoma with central nervous system involvement"],"prefix":"10.3389","volume":"16","author":[{"given":"Milda","family":"Mikalonyt\u0117","sequence":"first","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]},{"name":"Hematology and Oncology Department, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilhelmas","family":"Landsbergis","sequence":"additional","affiliation":[{"name":"Hematology and Oncology Department, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Kevli\u010dius","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skirmant\u0117","family":"\u010cernauskien\u0117","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]},{"name":"Hematology and Oncology Department, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linas","family":"Davainis","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrius","family":"\u017du\u010denka","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]},{"name":"Hematology and Oncology Department, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igoris","family":"Trociukas","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Pileckyt\u0117","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]},{"name":"Hematology and Oncology Department, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birut\u0117","family":"Davainien\u0117","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"\u0160lepikien\u0117","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gintar\u0117","family":"Ra\u017eanskien\u0117","sequence":"additional","affiliation":[{"name":"National Centre of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugnius","family":"Mickys","sequence":"additional","affiliation":[{"name":"National Centre of Pathology, Affiliate of Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Ra\u017eanskas","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u016brat\u0117","family":"Dementavi\u010dien\u0117","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindaugas","family":"Sto\u0161kus","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raminta","family":"Batiu\u0161kait\u0117","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laimonas","family":"Gri\u0161kevi\u010dius","sequence":"additional","affiliation":[{"name":"Hematology, Oncology and Transfusion Medicine Centre, Vilnius University Hospital Santaros Klinikos","place":["Vilnius, Lithuania"]},{"name":"Hematology and Oncology Department, Faculty of Medicine, Institute of Clinical Medicine, Vilnius University","place":["Vilnius, Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909","article-title":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","article-title":"The biology and management of systemic anaplastic large cell lymphoma","volume":"126","author":"Hapgood","year":"2015","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2021.5232","article-title":"Traditional and emerging therapies for anaplastic large cell lymphoma (review)","volume":"59","author":"Sun","year":"2021","journal-title":"Int J Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-060715","article-title":"Pathobiology of ALK+ anaplastic large-cell lymphoma","volume":"110","author":"Amin","year":"2007","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.2083","article-title":"Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath Network","volume":"35","author":"Laurent","year":"2017","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.213512","article-title":"ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients","volume":"104","author":"Sibon","year":"2019","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqac046","article-title":"Primary central nervous system anaplastic large cell lymphoma, ALK positive","volume":"158","author":"Ahrendsen","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191461","article-title":"The risk of central nervous system relapses in patients with peripheral T-cell lymphoma","volume":"13","author":"Chihara","year":"2018","journal-title":"PloS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4749452","article-title":"Alectinib monotherapy in isolated central nervous system relapse of ALK-positive anaplastic large cell lymphoma","volume":"2022","author":"Verran","year":"2022","journal-title":"Case Rep Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v8.i9.1685","article-title":"Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC\/ALK translocation treated with alectinib: a case report","volume":"8","author":"Yang","year":"2020","journal-title":"World J Clin cases"},{"key":"B12","doi-asserted-by":"publisher","first-page":"106164","DOI":"10.1016\/j.leukres.2019.05.014","article-title":"Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib","volume":"83","author":"Tomlinson","year":"2019","journal-title":"Leuk Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.001","article-title":"Treatment of refractory ALK rearranged anaplastic large cell lymphoma with alectinib","volume":"19","author":"Reed","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280081","article-title":"Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement","volume":"107","author":"Rigaud","year":"2022","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-780049","article-title":"Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma","volume":"130","author":"Pro","year":"2017","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.7.2399","article-title":"High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis","volume":"96","author":"Kewalramani","year":"2000","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.739286","article-title":"Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma","volume":"54","author":"Yao","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2746-3","article-title":"ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin","volume":"95","author":"Abid","year":"2016","journal-title":"Ann Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00557","article-title":"ALK inhibitors in the treatment of ALK positive NSCLC","volume":"8","author":"Khan","year":"2019","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1177\/1758834015617355","article-title":"ALK inhibitors in non-small cell lung cancer: the latest evidence and developments","volume":"8","author":"Sullivan","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0689-7","article-title":"Clinical pharmacokinetics of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer","volume":"58","author":"Hirota","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14671","article-title":"Alectinib for relapsed or refractory anaplastic lymphoma kinase\u2010positive anaplastic large cell lymphoma: an open\u2010label phase II trial","volume":"111","author":"Fukano","year":"2020","journal-title":"Cancer Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2056","article-title":"Evaluation of lorlatinib cerebrospinal fluid concentrations in relation to target concentrations for anaplastic lymphoma kinase (ALK) inhibition","volume":"62","author":"Sun","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3171\/CASE25522","article-title":"Anaplastic lymphoma kinase\u2013positive primary CNS anaplastic large cell lymphoma in a pediatric patient: illustrative case","volume":"10","author":"Dolen Burak","year":"2025","journal-title":"J Neurosurg Case Lessons"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s44228-023-00038-6","article-title":"Refractory anaplastic large cell lymphoma rescued by the combination of the second-generation ALK inhibitor brigatinib, high-dose chemotherapy and allogeneic stem cell transplantation: a case report and review of the literature","volume":"5","author":"Caddeo","year":"2023","journal-title":"Clin Hematol Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2402419","article-title":"Brigatinib in ALK-positive ALCL after failure of brentuximab vedotin","volume":"390","author":"Veleanu","year":"2024","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.874462","article-title":"Peripheral T-cell lymphomas involving the central nervous system: a report from the Czech Lymphoma Study Group Registry","volume":"12","author":"Mocikova","year":"2022","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2013.110","article-title":"Clinical presentation of anaplastic large-cell lymphoma in the central nervous system","volume":"1","author":"Nomura","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.109","article-title":"Primary CNS lymphoma of T-cell origin: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group","volume":"23","author":"Shenkier","year":"2005","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2025.100524","article-title":"Involvement of the central nervous system in relapsed T-cell lymphoma: insights from four case studies","volume":"24","author":"Chiriac","year":"2025","journal-title":"Leuk Res Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1511045","article-title":"Abrupt relapse of ALK -positive lymphoma after discontinuation of crizotinib","volume":"374","author":"Gambacorti-Passerini","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1679620\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T04:28:08Z","timestamp":1780979288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1679620\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1679620"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1679620","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"article-number":"1679620"}}